We are live on ! Find out more
DYN icon

Dyne Therapeutics
DYN

83 hedge funds and large institutions have $573M invested in Dyne Therapeutics in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 9

14% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 21

9% more funds holding

Funds holding: 76 → 83 (+7)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

1.15% less ownership

Funds ownership: 69.92% → 68.77% (-1.1%)

24% less capital invested

Capital invested by funds: $753M → $573M (-$180M)

Holders
83
Holders Change
+7
Holders Change %
+9.21%
% of All Funds
1.45%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
16
Increased
24
Reduced
21
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$27.7M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.59M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.49M
4
Norges Bank
Norges Bank
Norway
+$2.08M
5
IBT
International Biotechnology Trust
United Kingdom
+$2.04M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$26.8M
2
DM
Deerfield Management
New York
-$16.6M
3
O
OrbiMed
New York
-$7.36M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$4.1M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$2.64M
Name Holding Trade Value Shares
Change 		Change in
Stake
SFM
26
Sphera Funds Management
Israel
$3.65M -$2.56M -144,631 -39%
EC
27
EcoR1 Capital
California
$3.57M – – –
WP
28
Woodline Partners
California
$3.51M -$109K -6,173 -3%
Charles Schwab
29
Charles Schwab
California
$2.99M +$577K +32,557 +21%
SCM
30
Soleus Capital Management
Connecticut
$2.9M – – –
ACH
31
ArrowMark Colorado Holdings
Colorado
$2.74M – – –
ACM
32
Altium Capital Management
New York
$2.71M – – –
N
33
Nuveen
North Carolina
$2.37M -$106K -5,953 -4%
Renaissance Technologies
34
Renaissance Technologies
New York
$2.28M +$2.49M +140,500 New
Two Sigma Investments
35
Two Sigma Investments
New York
$1.84M +$2.01M +113,204 New
HMC
36
Harvard Management Company
Massachusetts
$1.74M – – –
Morgan Stanley
37
Morgan Stanley
New York
$1.69M +$1.76M +99,122 +2,129%
JP Morgan Chase
38
JP Morgan Chase
New York
$1.52M +$1.38M +77,835 +491%
SG Americas Securities
39
SG Americas Securities
New York
$1.16M +$1.26M +71,317 New
Swiss National Bank
40
Swiss National Bank
Switzerland
$828K – – –
Adage Capital Partners
41
Adage Capital Partners
Massachusetts
$812K -$886K -50,000 -50%
Ensign Peak Advisors
42
Ensign Peak Advisors
Utah
$650K – – –
Goldman Sachs
43
Goldman Sachs
New York
$637K -$2.53M -142,877 -78%
State of Wisconsin Investment Board
44
State of Wisconsin Investment Board
Wisconsin
$632K +$19.4K +1,094 +3%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$623K +$24.8K +1,400 +4%
T. Rowe Price Associates
46
T. Rowe Price Associates
Maryland
$590K +$645K +36,358 New
California State Teachers Retirement System (CalSTRS)
47
California State Teachers Retirement System (CalSTRS)
California
$571K -$110K -6,228 -15%
First Trust Advisors
48
First Trust Advisors
Illinois
$568K +$620K +34,994 New
PMAM
49
Penn Mutual Asset Management
Pennsylvania
$567K +$619K +34,886 New
TI
50
Trexquant Investment
Connecticut
$452K +$494K +27,854 New
1
2
3 4

DYN Hedge Fund Activity: Q3 2021 in Review

83 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q3 2021, worth a combined $573M — down 24% from $753M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new DYN positions and 9 closed out — a net gain of 7 holders — while 24 added to existing stakes and 21 trimmed.

The largest buyer was Logos Global Management, adding an estimated $27.7M. The largest seller was Wellington Management Group, cutting an estimated $26.8M.

  • 83 institutional investors held Dyne Therapeutics (DYN) as of Q3 2021, up from 76 in Q2 2021.
  • Funds reported $573M of Dyne Therapeutics stock for Q3 2021, down 24% quarter-over-quarter.
  • 16 funds opened new Dyne Therapeutics positions in Q3 2021 and 9 closed out, a net change of +7 holders.
  • The largest Dyne Therapeutics buyer in Q3 2021 was Logos Global Management, an estimated $27.7M added.
  • The largest Dyne Therapeutics seller in Q3 2021 was Wellington Management Group, an estimated $26.8M sold.

Based on aggregated 13F filings for Q3 2021.